Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Bouncing Back Today

By Keith Speights – Sep 14, 2021 at 11:30AM

Key Points

  • Moderna stock fell on Monday after the publication of a scientific paper opposing booster doses.
  • Shares appear to be rebounding today as investors realize any short-term decisions on boosters aren't likely to impact Moderna very much.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be buying on the dip after yesterday's sell-off.

What happened

Shares of Moderna (MRNA -0.23%) were bouncing back by 3.6% as of 11:04 a.m. EDT on Tuesday after falling 6% on Monday. The rebound appears to be due to investors buying on the dip after digesting news that some top scientists are opposing booster doses for messenger RNA vaccines.

So what

There's a pretty good case to be made that yesterday's sell-off of vaccine stocks was overdone. For one thing, it remains to be seen what impact that opposition to boosters will have on upcoming U.S. government decisions. 

A healthcare professional giving a shot to a person.

Image source: Getty Images.

More importantly, though, the U.S. has already bought enough COVID-19 vaccine doses to provide boosters for all Americans. Even if boosters aren't given a green light, it won't have much financial impact (if any) on Moderna over the near term.

In addition, the group of scientists that contributed to a paper published in The Lancet on Monday acknowledged that boosters might be required if the efficacy of current vaccines declines. Moderna could still benefit if boosters are indeed needed over the longer term.

Now what

The Food and Drug Administration is convening an advisory panel on Friday to discuss booster doses. Moderna's share price could experience another swing, either up or down, based on what the panel recommends.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.